Metastatic Pancreatic Cancer: ASCO Guideline Update
Davendra Sohal, Erin B. Kennedy, Pelin Cinar, Thierry Conroy, Mehmet Sitki Copur, Christopher H. Crane, Ignacio Garrido‐Laguna, Michelle Lau, Tyler Johnson, Smitha Krishnamurthi, Cassadie Moravek, Eileen M. O’Reilly, Philip A. Philip, Shubham Pant, Manish A. Shah, Vaibhav Sahai, Hope E. Uronis, Neeha Zaidi, Daniel A. Laheru
Abstract
PURPOSE: The aim of this work was to provide an update to the ASCO guideline on metastatic pancreatic cancer pertaining to recommendations for therapy options after first-line treatment. METHODS: ASCO convened an Expert Panel and conducted a systematic review to update guideline recommendations for second-line therapy for metastatic pancreatic cancer. RESULTS: One randomized controlled trial of olaparib versus placebo, one report on phase I and II studies of larotrectinib, and one report on phase I and II studies of entrectinib met the inclusion criteria and inform the guideline update. RECOMMENDATIONS: mutations, and TRK alterations are provided for all treatment-eligible patients to select patients for recommended therapies, including pembrolizumab, olaparib, larotrectinib, or entrectinib, or potential clinical trials. The Expert Panel continues to endorse the remaining recommendations for second-line chemotherapy, as well as other recommendations related to treatment, follow-up, and palliative care from the 2018 version of this guideline. Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines.